Literature DB >> 4188117

L-dopa for progressive supranuclear palsy.

H L Klawans.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1969        PMID： 4188117

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

Review 1.  Progressive supranuclear palsy: clinical features, pathophysiology and management.

Authors:  A Rajput; A H Rajput
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 2.  Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.

Authors:  R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1971       Impact factor: 9.546

Review 3.  Dopamine and disease.

Authors:  A Barbeau
Journal:  Can Med Assoc J       Date:  1970-10-17       Impact factor: 8.262

4.  Reversible supranuclear ophthalmoplegia associated with Parkinsonism.

Authors:  R J Guiloff; R J George; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-06       Impact factor: 10.154

5.  [Progressive supranuclear palsy].

Authors:  H J Colmant
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1971
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.